For decades, the standard liver fat treatment was a shrug. Patients were told to lose weight and come back in a year. When they came back, the labs were the same or worse. That era ended in March 2024, when the FDA approved Rezdiffra, the first medication ever approved for MASH. MASH is the progressive form of fatty liver disease where fat, inflammation and scarring damage the liver together. This guide explains who actually qualifies for it, what it does to the liver, what it costs, what it does not do and how it fits beside the metabolic treatment that should surround it.
- Rezdiffra (resmetirom) was approved by the FDA in March 2024 as the first treatment for noncirrhotic MASH with moderate to advanced fibrosis.
- It is indicated for adults with F2 or F3 fibrosis, which means the diagnosis depends on proper staging rather than an ALT number alone.
- It reduces liver fat, inflammation and fibrosis drive through a selective thyroid hormone receptor beta mechanism that acts mainly in the liver.
- It does not cure the metabolic drivers behind fatty liver, so it works alongside weight and metabolic treatment rather than instead of it.
- List price runs commonly around $47,000 per year, which makes the prescription conversation and any markup question worth asking directly.
Why fatty liver finally got a drug
MASH, formerly called NASH, is the stage of fatty liver disease where fat accumulation has progressed to inflammation and scarring. Left alone it can advance toward cirrhosis, liver failure and liver cancer and it is already one of the fastest growing reasons for liver transplant in the United States. The reason it took until 2024 to get an approved drug is that the liver is a difficult organ to medicate, because early attempts either failed to reach the right targets or produced side effects elsewhere in the body.
Rezdiffra was built around a specific answer to that problem. It is a selective agonist of thyroid hormone receptor beta, a receptor that sits heavily in liver tissue and governs how the liver handles fat. Activating it pushes the liver to burn fat rather than store it, which reduces fat accumulation, inflammation and the fibrosis drive behind them, while largely sparing the heart and other tissues that widespread thyroid activation would affect.
Who actually qualifies
The approval is narrow and the narrowness matters. Rezdiffra is approved for adults with noncirrhotic MASH with moderate to advanced fibrosis, which means stage F2 or F3 on the standard fibrosis scale. It is not approved for simple fatty liver without scarring and it is not approved once cirrhosis has developed.
That makes staging the real gate. Most people with fatty liver have never been staged, because a routine ALT blood test cannot distinguish a fat-filled but healthy liver from one with active scarring. Proper workup usually begins with a FIB-4 score calculated from routine bloodwork, moves to an elastography scan when the score raises concern and occasionally reaches a biopsy decision where imaging leaves the answer ambiguous. Patients often discover their stage for the first time inside a proper metabolic evaluation rather than a liver specialty visit, because fatty liver clusters with insulin resistance, elevated ApoB and central adiposity and is found by looking for them.
What each fibrosis stage means
| Stage | What it describes | Treatment posture |
|---|---|---|
| F0 to F1 | Fat with little or no scarring | Weight, metabolic and lifestyle treatment, no MASH drug indicated |
| F2 | Moderate scarring, portal tract involvement | Drug eligible window opens, Rezdiffra indication begins |
| F3 | Advanced scarring, bridging fibrosis | Drug eligible window, the highest-stakes zone before cirrhosis |
| F4 | Cirrhosis | Rezdiffra is not approved here, transplant-stage monitoring begins |
What the trial showed
The pivotal trial randomized patients with F2 and F3 disease and measured two things that matter. First, MASH resolution without worsening of fibrosis, which happened in a clear majority of patients on Rezdiffra at both tested doses, versus a substantially smaller share on placebo. Second, fibrosis improvement by at least one stage without MASH worsening, which happened in a meaningful minority on drug versus fewer on placebo. The effects were consistent across both doses tested and the drug was generally well tolerated, with the most common side effects being diarrhea and nausea, usually mild to moderate.


What it does not do
Rezdiffra treats the liver disease process. It does not treat the reasons the liver got sick, which live in the same metabolic system that drives insulin resistance, dyslipidemia and visceral fat. A patient who takes the drug while weight, glucose and ApoB go unmanaged is treating a symptom layer while the engine keeps running. It also does not reverse established cirrhosis and it is not a substitute for the follow-up imaging that staging requires.
This is exactly why we read liver health inside the cardiometabolic picture rather than as a separate organ problem. Fatty liver, insulin resistance and elevated ApoB are one system wearing three lab coats and the treatment plan should reflect that rather than parcel it out to three specialists who never see each other's notes.
What it costs and what we do about it
Rezdiffra is expensive. List price runs commonly around $47,000 per year and actual out-of-pocket cost depends heavily on insurance coverage, manufacturer assistance and pharmacy arrangements. We have no arrangement with any manufacturer and no markup on any prescription, so whatever your pharmacy charges for this drug is what you pay and we take nothing from it. If your clinician and your staging support adding Rezdiffra to your plan, the pharmacy cost arrives as its own bill with our fee untouched, which is how every medication in our model works.
The honest counterweight to that price is that for many patients the highest-value liver intervention is still the cheapest one to start, which is meaningful weight reduction and for patients who qualify a GLP-1 medication addresses the metabolic drivers that Rezdiffra leaves standing. The two drugs do different jobs and for many patients the rational answer is both, with the combination decided by a clinician who has your fibrosis stage and your metabolic panel in front of them.
What to do this month
If your labs have ever shown elevated liver enzymes or your chart mentions fatty liver and nobody staged it, the next step is a proper workup rather than another year of waiting. Ask specifically for a FIB-4 score from your existing bloodwork and whether elastography is warranted. If your metabolic panel has never been read as one system, that is the gap worth closing, because liver health improves fastest when weight, glucose, lipids and inflammation are treated together.
If you want clinicians who treat liver fat as part of one metabolic system rather than an isolated organ complaint, check your eligibility or read our guide to cardiometabolic optimization.
FAQ
Is there an FDA-approved drug for fatty liver disease? Yes. In March 2024 the FDA approved Rezdiffra (resmetirom), the first medication approved for noncirrhotic MASH with moderate to advanced fibrosis, which is fatty liver disease with scarring. It is indicated alongside diet and exercise for adults with stage F2 or F3 fibrosis.
Who qualifies for Rezdiffra? Adults with noncirrhotic MASH and moderate to advanced fibrosis, meaning F2 or F3 on staging. Reaching that answer usually takes blood-based scoring such as FIB-4, imaging such as elastography and sometimes a biopsy decision, which is why the workup deserves a clinician rather than an app.
What does Rezdiffra do? It is a selective thyroid hormone receptor beta agonist that acts mainly in the liver, reducing fat accumulation, inflammation and fibrosis drive. In its pivotal trial a clear majority of patients on Rezdiffra saw MASH resolution with no worsening of fibrosis and a meaningful share saw fibrosis improve by at least one stage.
What does Rezdiffra not do? It does not fix the metabolic drivers that produced the liver fat in the first place, it is not approved for cirrhosis and stopping it while the drivers remain means the disease process resumes. It works best as one layer on top of weight and metabolic treatment, never instead of it.
How much does Rezdiffra cost? Commonly around $47,000 per year at list price, though actual out-of-pocket cost varies widely by coverage and assistance programs. Our membership never marks up any prescription, so your pharmacy bills you its own cost on this or any other drug.
Can Rezdiffra be combined with a GLP-1? Yes and the combination is rational for many patients because the drugs act on different layers, the liver disease process and the metabolic drivers behind it. Combination decisions belong with a clinician who has your fibrosis staging and your metabolic panel in front of them.
Does fatty liver always need medication? No. Early disease without significant fibrosis is managed primarily through weight, metabolic and lifestyle treatment and meaningful weight loss remains the single most effective intervention for fatty liver at any stage. Medication enters the picture when fibrosis has progressed to F2 or F3.
How do I find out my fibrosis stage? Through a staged workup that usually starts with a FIB-4 blood score, moves to imaging such as elastography when the score suggests risk and occasionally includes biopsy. Every Biomarker Audit in our membership includes the labs that feed that first calculation, so the question gets asked on a schedule rather than never.
Related Reading
- Cardiometabolic optimization: the definitive guide
- Biomarker audits vs standard blood tests
- How to reverse insulin resistance with medical support
- Direct primary care vs insurance
References
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease (FDA press announcement, March 2024). 2024. www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
- FDA approves resmetirom (Rezdiffra) for noncirrhotic NASH with moderate to advanced fibrosis. 2024. www.fda.gov/drugs/fda-approved-drugs/rezdiffra-resmetirom-tablets